BMED Stock Analysis: Banca Mediolanum | MI
Banks - Regional | MI, Italy | Market Cap: 17.803m EUR | 12M Return: 48.2% | IT0004776628 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 16.3M
EPS Trend: 94.4%
Qual. Beats: 0
Rev. Trend: 95.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Banca Mediolanum S.p.A. is an Italian financial services company headquartered in Basiglio, founded in 1982. It provides a wide range of retail banking products, including current accounts, deposits, mortgage and personal loans, as well as credit, debit, and prepaid cards. Beyond traditional banking, the company offers investment products such as mutual funds, unit-linked policies, trading and asset management services, and bond issues, along with insurance coverage spanning life, health, serious illness, and family protection. It also distributes a set of branded assistance products under the SelfyCare line covering veterinary, travel, and life-project needs.
The company operates within Italys diversified financials sector and follows a bancassurance-style model, bundling banking, asset management, and insurance distribution through a single integrated platform aimed at household customers. It is listed on the Milan Stock Exchange under the ticker BMED and is classified as a large-cap stock within the GICS Diversified Financial Services sub-industry.
- ECB rate cuts pressure net interest margin
- Managed assets growth drives fee income expansion
- Financial advisor network productivity underpins client acquisition
| Net Income: 1.32b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.82 > 1.0 |
| NWC/Revenue: -97.74% < 20% (prev -1.63k%; Δ 1.53k% < -1%) |
| CFO/TA 0.05 > 3% & CFO 5.10b > Net Income 1.32b |
| Net Debt (5.00b) to EBITDA (1.57b): 3.17 < 3 |
| Current Ratio: 0.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (745.5m) vs 12m ago -0.13% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 4.45% > 50% (prev 3.47%; Δ 0.98% > 0%) |
| Interest Coverage Ratio: 4.21 > 6 (EBIT TTM 1.55b / Interest Expense TTM 368.9m) |
| A: -0.04 (Total Current Assets 555.8m - Total Current Liabilities 4.59b) / Total Assets 99.1b |
| B: 0.01 (Retained Earnings 555.5m / Total Assets 99.1b) |
| C: 0.02 (EBIT TTM 1.55b / Avg Total Assets 92.6b) |
| D: 0.05 (Book Value of Equity 4.58b / Total Liabilities 94.5b) |
| Altman-Z'' = -0.08 = B |
| DSRI: 1.02 (Receivables 719.0m/511.5m, Revenue 4.12b/2.98b) |
| GMI: 0.85 (GM 82.06% / 96.06%) |
| AQI: 1.00 (AQ_t 0.99 / AQ_t-1 0.99) |
| SGI: 1.38 (Revenue 4.12b / 2.98b) |
| TATA: -0.04 (NI 1.32b - CFO 5.10b) / TA 99.1b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of October 06, 2026, the stock is trading at EUR 23.49 with a total of 746,128 shares traded. Over the past week, the price has changed by -0.34%, over one month by +1.12%, over three months by +3.53% and over the past year by +48.24%.
Current recommended Stop Loss: 22.40 (which is 4.6% or 2.2 ATR below the current price).
Banca Mediolanum has no consensus analysts rating.
P/E Trailing = 13.5
P/E Forward = 11.1111
P/S = 6.9531
P/B = 3.8055
P/EG = 0.2308
Revenue TTM = 4.12b EUR
EBIT TTM = 1.55b EUR
EBITDA TTM = 1.57b EUR
Long Term Debt = 647.1m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 4.59b EUR (from shortTermDebt, last quarter)
Debt = 5.19b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.00b EUR (calculated: Debt 5.19b - CCE 187.0m)
Enterprise Value = 22.8b EUR (17.8b + Debt 5.19b - CCE 187.0m)
Interest Coverage Ratio = 4.21 (Ebit TTM 1.55b / Interest Expense TTM 368.9m)
EV/FCF = 4.48x (Enterprise Value 22.8b / FCF TTM 5.10b)
FCF Yield = 22.34% (FCF TTM 5.10b / Enterprise Value 22.8b)
FCF Margin = 123.6% (FCF TTM 5.10b / Revenue TTM 4.12b)
Net Margin = 31.93% (Net Income TTM 1.32b / Revenue TTM 4.12b)
Gross Margin = unknown ((Revenue TTM 4.12b - Cost of Revenue TTM 162.3m) / Revenue TTM)
Tobins Q-Ratio = 0.23 (Enterprise Value 22.8b / Total Assets 99.1b)
Interest Expense / Debt = 7.11% (Interest Expense 368.9m / Debt 5.19b)
Taxrate = 15.21% (236.0m / 1.55b)
NOPAT = 1.32b (EBIT 1.55b * (1 - 15.21%))
Current Ratio = 0.12 (Total Current Assets 555.8m / Total Current Liabilities 4.59b)
Debt / Equity = 1.13 (Debt 5.19b / totalStockholderEquity, last quarter 4.58b)
Debt / EBITDA = 3.17 (Net Debt 5.00b / EBITDA 1.57b)
Debt / FCF = 0.98 (Net Debt 5.00b / FCF TTM 5.10b)
Total Stockholder Equity = 4.57b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.42% (Net Income 1.32b / Total Assets 99.1b)
RoE = 28.80% (Net Income TTM 1.32b / Total Stockholder Equity 4.57b)
RoCE = 29.75% (EBIT 1.55b / Capital Employed (Equity 4.57b + L.T.Debt 647.1m))
RoIC = 1.33% (NOPAT 1.32b / Invested Capital 99.0b)
WACC = 7.56% (E(17.8b)/V(23.0b) * Re(8.01%) + D(5.19b)/V(23.0b) * Rd(7.11%) * (1-Tc(0.15)))
Discount Rate = 8.01% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -45.82 | Cagr: 0.03%
[DCF] Terminal Value 77.97% ; FCFF base≈3.51b ; Y1≈4.03b ; Y5≈5.92b
[DCF] Fair Price = 113.6 (EV 89.2b - Net Debt 5.00b = Equity 84.2b / Shares 740.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.44 | EPS CAGR: 25.13% | SUE: 0.58 | # QB: 0
Revenue Correlation: 95.30 | Revenue CAGR: 22.16% | SUE: 0.15 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.37 | Chg30d=+0.00% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=1.55 | Chg30d=+1.46% | Revisions=+67% | GrowthEPS=-0.9% | GrowthRev=-31.6%
EPS next Year (2027-12-31): EPS=1.58 | Chg30d=+0.40% | Revisions=+70% | GrowthEPS=+1.6% | GrowthRev=+5.4%
[Analyst] Revisions Ratio: +82% (up=14, down=0)